GANZYK-RTU Drug Patent Profile
✉ Email this page to a colleague
When do Ganzyk-rtu patents expire, and when can generic versions of Ganzyk-rtu launch?
Ganzyk-rtu is a drug marketed by Exela Pharma and is included in one NDA. There is one patent protecting this drug.
The generic ingredient in GANZYK-RTU is ganciclovir. There are twenty-seven drug master file entries for this compound. Two suppliers are listed for this compound. Additional details are available on the ganciclovir profile page.
DrugPatentWatch® Generic Entry Outlook for Ganzyk-rtu
Indicators of Generic Entry
Summary for GANZYK-RTU
| US Patents: | 1 |
| Applicants: | 1 |
| NDAs: | 1 |
| Finished Product Suppliers / Packagers: | 1 |
| Formulation / Manufacturing: | see details |
| DailyMed Link: | GANZYK-RTU at DailyMed |
Pharmacology for GANZYK-RTU
| Drug Class | Cytomegalovirus Nucleoside Analog DNA Polymerase Inhibitor Nucleoside Analog Antiviral |
| Mechanism of Action | DNA Polymerase Inhibitors |
Anatomical Therapeutic Chemical (ATC) Classes for GANZYK-RTU
US Patents and Regulatory Information for GANZYK-RTU
GANZYK-RTU is protected by one US patents.
Patents protecting GANZYK-RTU
Ganciclovir compositions and related methods
Patent Number: See Plans and Pricing
Patent Expiration: See Plans and Pricing
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Exela Pharma | GANZYK-RTU | ganciclovir | SOLUTION;INTRAVENOUS | 209347-001 | Feb 17, 2017 | RX | Yes | Yes | See Plans and Pricing | See Plans and Pricing | Y | See Plans and Pricing | |||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
